Please use this identifier to cite or link to this item:
Title: Mineralocorticoid Receptor Antagonists—A New Sprinkle of Salt and Youth
Authors: Olivera M.
Lindley L.
Jozic, Ivan
Tomic-Canic M.
Journal: Journal of Investigative Dermatology
Issue Date: 1-Oct-2016
Abstract: © 2016 The Authors Skin atrophy and impaired cutaneous wound healing are the recognized side effects of topical glucocorticoid (GC) therapy. Although GCs have high affinity for the glucocorticoid receptor, they also bind and activate the mineralocorticoid receptor. In light of this, one can speculate that some of the GC-mediated side effects can be remedied by blocking activation of the mineralocorticoid receptor. Indeed, according to Nguyen et al., local inhibition of the mineralocorticoid receptor via antagonists (spironolactone, canrenoate, and eplerenone) rescues GC-induced delayed epithelialization and accelerates wound closure in diabetic animals by targeting epithelial sodium channels and stimulating keratinocyte proliferation. These findings suggest that the use of mineralocorticoid receptor antagonists coupled with GC therapy may be beneficial in overcoming at least some of the GC-mediated side effects.
Type: Note
DOI: 10.1016/j.jid.2016.07.025
ISSN: 0022202X
SCOPUS: 84996956048
Appears in Collections:University Library, Kragujevac
[ Google Scholar ]

Page views(s)


Files in This Item:
File Description SizeFormat 
10.1016-j.jid.2016.07.025.pdf746.92 kBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.